

OECD Guidance for Industry Data Submissions
for Pheromones and other Semiochemicals
and their Active Substances

(Dossier Guidance for Pheromones and other Semiochemicals)

Guidelines and Criteria for Industry for the Preparation and Presentation of Complete Dossiers and of Summary Dossiers for Pheromones and other Semiochemicals and their Active Substances in Support of Regulatory Decisions in OECD Countries

- 2003 -

- *OECD Environment Directorate* -

FOREWORD

This document is intended to provide guidance to applicants wishing to have active substances and/or formulated products approved, which are pheromones or semiochemicals or plant protection products, which contain only active substances known as pheromones or semiochemicals. For plant protection products containing other active substances, applicants are referred to the OECD Guidance for Industry Data Submissions on Plant Protection Products and their Active Substances (Dossier Guidance).

Data requirements for registration that are specific to semiochemical pest control products would facilitate access to this reduced risk technology. In developing a regulatory approach for arthropod semiochemicals, the inherent differences between these products and conventional chemical pesticides were taken into consideration. Semiochemicals act by modifying behaviour of the pest species rather than killing it, are more target specific than conventional insecticides, are used at concentrations close to those in nature, and dissipate rapidly. For these reasons it is expected that most semiochemical products pose low potential risk to human health and the environment compared with conventional pesticides. Environmental and health studies have demonstrated that these substances pose minimal risk and may provide effective pest control at low volumes.

Based on this rationale, the data set is reduced relative to conventional pesticides.

The guidance for registration requirements for pheromones and other semiochemicals set forth by the OECD are outlined in Appendix 2. This guidance does not make any prejudice to the expert judgement of regulatory authorities in individual cases.

Special attention should be made to Straight-Chained Lepidopteran Pheromones (SCLPs). For regulatory purposes, SCLPs are pheromones with a well-defined unbranched aliphatic structure, which is characteristic of most known pheromones produced by members of the order Lepidoptera.

The document provides guidance with respect to the format and presentation of the documentation to be submitted. MRLs and or import tolerances are not normally established for these types of products. However, if necessary, relevant guidance can be found in the OECD Guidance for Industry Data Submissions on Plant Protection Products and their Active Substances (Dossier Guidance).

Arthropod semiochemicals are inherently different from conventional pesticides in their non-toxic, target-specific mode of action and natural occurrence. They are generally effective at very low rates, comparable to levels that occur naturally. They are generally volatile and usually dissipate rapidly in the environment. As well, many end use products are formulated in passive dispensers (hollow fibers, tapes) that present little direct exposure to humans and nontarget organisms. All these factors effectively minimize the risk of adverse effects from the use of semiochemicals. The data required to chemically characterize a semiochemical pest control product and to demonstrate how it is most effectively used, are the same as for conventional pesticides. However, substantial reductions in health and environmental data requirements are available for SCLPs (Touhey 1990). Also for other classes of semiochemicals, it may be justified to waive certain required studies if an adequate rationale can be provided by the registrant.

The numbering system in this document is based on the "*Guidelines and Criteria for Industry for the Preparation and Presentation of Complete Dossiers and of Summary Dossiers for Plant Protection Products and their Active Substances in Support of Regulatory Decisions in OECD Countries*" (Please consult the OECD Pesticide Web site at <http://www.oecd.org/ehs/pesticid.htm> or contact the OECD Secretariat for the latest version of this document). The numbering system in *this* document is not sequential, as requirements that do not relate to pheromones have been removed. However, in an attempt to avoid confusion, and to illustrate parallel data requirements for plant protection products, the numbering system used for plant protection products is retained.

The summaries of data and information included in the appendices to these guidelines are intended to be illustrative of the approach to be taken in the preparation of the comprehensive summaries required. The appendices concerned have not been critically examined for their technical content.

This guidance was developed with the aim of facilitating the compilation of data submissions to OECD countries by providing a common format and structure for their preparation, thereby reducing the need for resource-intensive re-formatting, re-structuring and re-writing for individual countries. A common format also facilitates (1) the use of electronic data submissions, and (2) the preparation of countries' review reports to a similar format and structure (monographs), thus allowing better mutual use of review reports and burden-sharing among countries. The preparation of dossiers and monographs according to a common format and structure will contribute to cost savings for both governments and industry.

Where on particular points of detail, additional or more detailed guidance is required, applicants and other interested parties are advised to contact the relevant authority of the country to which the documentation is to be submitted.

This guidance document is based on and is consistent with the Guidelines and criteria for the preparation and presentation of complete dossiers and of summary dossiers for the inclusion of active substances in Annex I of Directive 91/414/EEC (Article 5.3 and 8.2), issued by the European Commission (Commission Document 1663/VI/94, rev 8 of 22 April 1998) and was prepared with the benefit of the comments provided by the delegations of countries participating in the OECD Working Group on Pesticides and by pesticide industry representatives. The summaries of data and information included in the appendices to these guidelines relate to a different active substance to that addressed in the European Commission Guidelines. The appendices to this guidance document are consistent in overall form and structure with those appended to the European Commission Guidelines.

Note:

This document will be periodically revised, as some sections will be added or updated. Please consult the OECD Pesticide Web site at <http://www.oecd.org/ehs/pesticid.htm> or contact the OECD Secretariat to make sure that you have the latest version. It is not intended that summaries of data and information in preparation or already prepared be revised to achieve compliance with revised versions of this document.

Pesticide Programme
Environment, Health and Safety Division
Environment Directorate
Organisation for Economic Co-operation and Development
2, rue André Pascal
75775 Paris Cedex 16
France

TABLE OF CONTENTS

	page number
FOREWORD	I
1 GENERAL INTRODUCTION	1
2 DOCUMENTATION REQUIRED	5
2.1 Introduction	5
2.2 Individual Documents Required	5
Document A Purpose (statement of the context in which the dossier is submitted)	5
Document B Task force information	6
Document C Labels and leaflets	6
Document D-1 Supported uses	6
Document D-2 Registered uses	6
Document E Deleted	
Document F Statements of intention to submit a dossier	7
Document G Regulatory position for formulants	7
Document H Safety data sheets for formulants	7
Document I Other available toxicological data on formulants	7
Document J Confidential information	7
Documents K Individual test and study reports	8
Documents L <i>Tier I</i> quality checks for individual tests and studies and reference lists	8
Documents M <i>Tier II</i> summaries and assessments of individual tests and studies and groups of tests and studies	8
Documents N <i>Tier III</i> overall summary and assessment, conclusions and proposed decision	8
Document O Completed forms for the checking of dossiers for completeness	8
2.3 Samples and Analytical Standards	10
3 DOSSIER SUMMARIES AND OVERALL ASSESSMENTS - DETAILED REQUIREMENTS	11
3.1 Dossier on the active substance	11
3.1.1 <i>Tier I</i> Quality Checks - Document L (active substance) (for individual tests and studies)	11
3.1.2 <i>Tier II</i> Summary - Document M (active substance) (Summary of separate sections of the active substance dossier)	15
3.2 Dossier on the formulated product	17
3.2.1 <i>Tier I</i> Quality Checks - Document L (formulation) (for individual tests and studies)	17
3.2.2 <i>Tier II</i> Summary - Document M (formulation) (Summary of separate sections of the formulated product dossier)	22

3.3	<i>Tier III</i> Overall Summary and Assessment (active substance and formulated product dossiers) - Document N	24
4	CHECKING OF DOSSIERS FOR COMPLETENESS	26
4.1	Introduction	26
4.2	Suggested Approach	26
	Endnotes	28
	Figure 1 Dossier structure and content	9
	Table 1 Order in which the reasoned statement of the conclusions reached by the applicant are to be presented	25
Appendix 1	Standard Terms, Abbreviations and Definitions	A1/1
	Part 1 Technical terms	A1/1
	Part 2 Terms specifically used for Pheromones and Semiochemicals	A1/9
	Part 3 Organisations and Publications	A1/10
	Part 4 Format for the compilation of listings of semiochemical names, common names, synonyms, trade names, code names for active substances, metabolites and formulations	A1/13
	Part 5 Preparation (Formulation) Types and Codes	A1/14
Appendix 2	Guidance for Registration Requirements for Pheromones and Other Semiochemicals Used for Arthropod Pest Control	A2/1
Appendix 3		
	Part 1 Form for use in reporting details of intended uses (GAP information)	A3/1
	Part 2 Form for use in reporting registered uses and actual uses	A3/2
Appendix 4	Format for compilation of <i>Tier I</i> quality checks	A4/1
	Part 1 Summary report - appropriate for studies conducted in accordance with the test guidelines currently specified	A4/1
	Example 1 Acute inhalation toxicity	A4/1
	Example 2 Request to waive data required for oral 90-day toxicity of the active substance to rodents	A4/2
	Example 3 Request to waive data required for <i>in vitro</i> genotoxicity testing - Bacterial assay for gene mutation	A4/2

	Example 4	Request to waive data required for residues	A4/3
	Example 5	Environmental fate	A4/3
	Example 6	Request to waive data required for acute toxicity of the active substance to fish	A4/4
	Example 7	Acute skin irritation study	A4/4
Appendix 5	Deleted (not normally required)		A5/1
Appendix 6	Format for the listing of test and study reports and other documentation		A 6/1
	Part 1	Listing by test and study type	A 6/1
	Part 2	Listing by author	A 6/8
	Part 3	Listing of test and study reports and published papers not submitted	A 6/15
	Part 4	OECD, EU, US, Canadian, Japanese and Australian numbering systems for data and information on active substances	A 6/18
	Part 5	OECD, EU, US Canadian, Japanese and Australian numbering systems for data and information on formulated products	A 6/52
Appendix 7	Format for the compilation of <i>Tier II</i> summaries for an active substance		A 7/1
	Part 1	Section 1 : Identity of the active substance; Physical and chemical properties of the active substance; Further information on the active substance; Proposals including justification of the proposals for the classification and labelling of the active substance	A 7/1
	Part 2	Section 2 : Analytical methods	A 7/11
	Part 3	Section 3 : Toxicological and Metabolism studies on the active substance	A 7/13
	Part 4	Section 4 : Residues in or on the treated products for Food and Feed	A 7/32
	Part 5	Section 5 : Fate and Behaviour in the Environment	A 7/33
Appendix 8	Format for the compilation of <i>Tier II</i> summaries - formulated product		A 8/1
	Part 1	Section 1: Identity of the plant protection product; Physical, chemical and technical properties of the plant protection product; Data on application; Further information on the plant protection product; Proposals including justification of the proposals for the classification and labelling of the plant protection product; Proposals for risk and safety phrases and the proposed label	A 8/1
	Part 2	Section 3 : Toxicological studies and exposure data and information	A 8/8

	Part 3 Section 6 : Ecotoxicological studies and risk assessment	A 8/17
	Part 4 Section 7 : Efficacy data and information	A 8/22
Appendix 9	Format for the listing of end points to be included in the <i>Tier III</i> overall summary and assessment	A9/1
Appendix 10	Format for the compilation of <i>Tier III</i> overall summaries and assessments	A 10/1
Appendix 11	Forms for use in checking dossiers for completeness	A 11/1
	Part 1 Evaluation Form 1 - for use in checking that the required supporting documentation has been provided	A 11/1
	Part 2 Evaluation Form 2 - for use in checking that the required Annex II and Annex III dossier summaries and an overall assessment, have been provided	A 11/3
	Part 3 Evaluation Form 3 - for use in checking that all test and study reports required in accordance with Annex IIP have been provided	A 11/5
	Part 4 Evaluation Form 4 - for use in checking that all test and study reports required in accordance with Annex IIIP have been provided	A 11/20
	Part 5 Evaluation Form 5 - for use in checking that the <i>Tier I</i> quality checks for individual test and studies are of acceptable quality	A 11/32

1 GENERAL INTRODUCTION

- 1.1 The guidance provided and criteria specified, apply to the preparation of complete dossiers and summary dossiers on pheromones and other semiochemicals, whether submitted in support of applications for approval of active substances of this class, for the registration of a plant protection product containing exclusively pheromones or other semiochemicals as active substances, MRs and or import tolerances are not normally established for these types of products. However, if necessary, relevant guidance can be found in Appendix 5 of the OECD Guidance for Industry Data Submissions on Plant Protection Products and their Active Substances (Dossier Guidance). For the purposes of this guidance document, a complete dossier consists of all the test and study reports (including individual animal data, where appropriate) to be submitted, together with the summaries of the tests and studies submitted and relevant supporting documentation, while a summary dossier consists of that same set of documentation, without the test and study reports.
- 1.2 This guidance document is intended to be relevant only for data submissions concerning pheromones or other semiochemicals. Data submissions concerning active substances other than pheromones or other semiochemicals should follow the principles and guidance laid down in the OECD Guidance for Industry Data Submissions on Plant Protection Products and their Active Substances (Dossier Guidance) or OECD Guidance for Industry Data Submissions on Microbial Pest Control Products and their Microbial Pest Control Agents (Dossier Guidance for Microbials). It is not intended that summaries of data and information in preparation or already prepared be revised to achieve compliance with revised versions of this document that are issued from time to time.
- 1.3 Without prejudice to legal provisions in individual countries, OECD guidance for registration data requirements and waiving criteria were defined for pheromones and semiochemicals and plant protection products containing exclusively active substances of this class for the orientation of applicants (see Appendix 3). However, for the reasons outlined under Point 1.6 below, the agreed standard format for Industry Data Submissions should be maintained as far as possible. In spite of the fact that certain data requirements may be waived and, consequently, certain documents (e.g. Document E) may not be required in many cases, applicants should still follow the suggested standardised dossier format and provide, where relevant, justification for waiving certain data requirements in lieu of the summary data requested.
- 1.4 While requiring standardization in general lay out, subject matter, terminology and units of measurement, applicants nevertheless are required to use expert judgement in preparing the documentation concerned. Within the constraints imposed by the provisions of the legal requirements of individual countries, applicants nevertheless should treat these guidelines as providing a degree of flexibility.
- 1.5 These guidelines and criteria apply to documentation submitted for consideration, whether submitted by applicants, or by other interested parties wishing to submit technical or scientific information, with regard to the potentially dangerous effects of active substances, plant protection products, or their residues, on human or animal health or the environment.
- 1.6 The objective is to achieve standardization, to the extent that is practicable and feasible, of the format and presentation of documentation submitted, with a view to:
- ensuring the quality and consistency of the documentation submitted;
 - facilitating efficiency and economy in the use of resources necessary for the preparation of that documentation;

- facilitating applicants in checking the completeness and quality of the documentation prior to its submission;
- facilitating the use of electronic media for the submission, archiving and retrieval of the documentation submitted;
- facilitating efficiency and economy in the use of resources necessary for its evaluation; and
- facilitating the development of burden sharing arrangements by regulatory authorities, thereby further increasing efficiency and economy in the use of evaluative resources.

1.7 Notwithstanding the clear need for evaluators, whether toxicologists, chemists or biologists, to assess original study reports and supporting data and information, summaries of the data base submitted are also required (dossier summaries), to facilitate:

- checking for completeness by applicants and by the regulatory authority concerned;
- evaluation and assessment of the documentation concerned by the regulatory authority concerned;
- evaluation and assessment of the documentation concerned by the committees established or convened for that purpose; and
- decision making by the relevant authority.

1.8 Accordingly, those wishing to submit data and information in support of proposals for the approval of an active substance, for the registration or re-registration of a plant protection product, are themselves required to summarize, evaluate and assess the data concerned in the light of the relevant evaluative and decision making criteria. They are also required to make proposals for the decision to be made in the light of their assessment of the data and information concerned, proposals which should be supported with statements as to the rationale used.

1.9 Forms, developed to facilitate checks to be carried out to ensure that all the necessary information, data and summaries have been included in dossiers submitted and which are to be completed and submitted by applicants, are also intended to be of benefit to applicants for the purposes of checking that all the necessary information, data and summaries have been included in dossiers being prepared for submission. Such forms in some cases have been developed, and in other cases are to be developed, by the regulatory authorities of the various OECD countries.

1.10 Standard Units, Terms and Abbreviations:

- Standard Units: The English language version of Standard International Units must be used in reporting and summarizing tests and studies, although other units, if desired or considered relevant, may be used in parentheses ¹,
- Standard Terms and Standard Abbreviations and Definitions In the interest of avoiding confusion, standard technical terms and abbreviations as specified in Appendix 1 must be used - this Appendix will be further developed as required. Where terms and abbreviations not listed are used, a concise explanation of each such term or abbreviation should be provided in the text when it is used for the first time. In addition, a listing of all such additional terms and abbreviations should be provided as an Annex to each relevant summary document.

1.11 Hard copies of complete and summary dossiers should be submitted. In addition, applicants could provide information in a suitable electronic form in accordance with the requirements of the relevant regulatory authority - applicants are advised to discuss the approach they propose using with the regulatory authority of the country to which they propose making application. A number of options for the electronic submission of information are available, and two possibilities are described below. However these do not preclude the use of other options:

Option 1: The summary dossier, which contains the summary and assessment Information and supporting documentation, but not the test and study reports, could be provided in a suitable word processor, and where appropriate, spreadsheet format, on diskette(s) or by other electronic media;

Option 2: The entire dossier, including test and study reports, individual animal data, historical control data, other relevant data and information, as well as the summary and assessment information and supporting documentation, could be provided using the CADDY electronic dossier interchange and archiving format, which utilizes CD-ROM technology. The CADDY system, prepared in accordance with an EU Specification, allows submission of study reports as image files and has provision for the summary dossier to be included on the CD-ROM in the form of word processor/spreadsheet files, as appropriate. The content of dossiers submitted in CADDY format is identical to that of hard copy versions submitted. Further information on CADDY can be obtained from the Crop Life International (CLI):

Crop Life International
Avenue Louise 143, B-1050 Brussels, Belgium
Phone: 32 2 542 04 10
Fax: 32 2 542 04 19
WWW: <http://www.croplife.org/>

Regardless of the option chosen, applicants are encouraged, where possible, to present information

in tabular form (*e.g.* GAP Tables (Documents D1 and D2), reference lists). Separate items of information such as the names of authors should be allocated to separate cell columns. A row should be allocated to each entry. Alternatively a spreadsheet format can be used. The recommended approach is intended to facilitate the subsequent manipulation of the information provided by the regulatory authority to which application is made.

- 1.12 Applicants wishing to obtain information as to the requirements of the various regulatory authorities with respect to the number of complete and summary dossiers to be submitted should contact the regulatory authority in the country to which application is to be made.

2 DOCUMENTATION REQUIRED

2.1 Introduction

2.1.1 The summary documentation to be prepared and submitted, should allow a comprehensive understanding of the application and facilitate evaluation and decision making having regard to the evaluative and decision making criteria which are relevant in the country to which application is made, notwithstanding the clear need for reference to the individual study reports and the detailed data (*e.g.* data on relevant variables for individual animals), during the course of evaluating the data base concerned.

2.1.2 The applicant's objective should be to produce summaries and assessments which, accurately reflect the conclusions that can be derived from the data and information submitted and includes a proposal, prepared by the applicant, for the decision to be taken by the relevant regulatory authority in the country to which application is made.

2.2 Individual Documents Required

The documentation required comprises a number of separate elements and should include, in the following order:

Document A

Purpose

A statement of the context in which the dossier is submitted:

- approval of a new pheromone or other semiochemical,
- approval of an existing pheromone or other semiochemical, registration of a plant protection product containing a new pheromone or other semiochemical,
- registration of a plant protection product containing an existing pheromone or other semiochemical,
- modification or removal of conditions or restrictions associated with the registration of a plant protection product,
- special review of the registration of a plant protection product, where indications exist suggesting that the conditions of registration are no longer satisfied,
- routine review of the registration of a plant protection product, anticipating expiry of the period for which registered,

Document B

Task Force Information

Where relevant, details of any task force that exists or is formed for the purposes of defending particular active substances. The information provided should include the following information:

- the membership of the task force and a contact point for the task force (name, address, telephone and telefax numbers and e-mail address),
- a contact point for each member of the task force (name, address, telephone and telefax numbers and e-mail address),
- the list of test and study reports which were generated by or on behalf of the task force - where some members of the task force share ownership of, or have access to, some but not all of the test and study reports, a clear indication should be provided as to the ownership of, and rights of access to, the individual test and study reports listed;

Document C

Labels and Leaflets

Where requested, copies of existing or proposed label(s) and where relevant leaflets for each of the preparations for which a dossier is submitted. Where relevant, a translation of the texts of labels and leaflets submitted;

Document D-1

Supported Uses

Details of the intended uses (uses that are being supported by the applicant, for which data have been provided or, where relevant, for which data are to be provided by a specified date) and conditions of use (GAPs), on both food and feed crops and on non food and feed crops in the territory of the country to which application is made, supported in relation to the proposed approval, registration (Document D-1) - the information concerned should be provided using forms as set out in Part 1 of Appendix 3. Uses which are not yet registered should be identified by means of an asterisk or footnote;

Document D-2

Registered Uses

For existing active substances, a list of current registered uses in the country to which application is made and an indication of whether, or not, actually used (Document D-2) - the information concerned should be provided using forms as set out in Part 2 of Appendix 3. The listing provided should include those uses which are currently registered but which are not being supported by the applicant. The information provided with respect to actual use, should identify those registrations that are not currently availed of (some uses or all uses), and further should describe those instances where the rate and manner of use in practice is more restrictive than is provided for in the existing registration (*e.g.* registered uses of a plant protection product for which the product is not currently commercialized; uses for which the maximum registered application rate is seldom if ever availed of);

Document F	Statements of Intention to Submit a Dossier Where in the case of the review of existing registrations, the commercial interests and other parties involved or concerned, are required to submit a statement of intention to submit, in due course, a dossier or dossiers, a copy of all such statements;
Documents G – I	Documentation on Formulants Unless a full data package is submitted for every formulant included in the preparation (ingredient other than active substance), the following:
Document G	A statement as to whether the substance is permitted in food, animal feeding stuffs, medicines or cosmetics in accordance with the legislation of the country to which application is made,
Document H	a copy of the safety data sheet, and
Document I	where requested, other available toxicological, exposure and environmental data;
Document J	Confidential Information Where relevant and desired, a statement to indicate the data and information involving industrial and commercial secrets for which confidentiality is requested, in accordance with the legislative provisions of the country to which application is made. To facilitate the secure handling of such information, it should be included in a separate file, where it is feasible to do so (<i>e.g.</i> details of manufacturing processes, detailed specifications of active substance and preparations and individual medical records). The file should be identified as containing industrial and commercial secrets. Where applicants wish to have data and information involving industrial and commercial secrets treated as confidential, applicants should: <ul style="list-style-type: none">• taking account of the legislative provisions of the country to which application is made, provide a listing of the data and information for which confidentiality is requested, clearly cross-referenced, for each item, to the relevant test and study reports, as well as to the dossier summaries and supporting documentation submitted - the listing should be included in the file referred to above,• for each item listed, provide a justification for the claim that it is, or constitutes, an industrial and commercial secret - the justifications should be included in the file referred to above, and• highlight other items of information for which confidentiality is requested, in relevant study reports, dossier summaries and supporting documentation (<i>e.g.</i> identity of test laboratories);

**Document K
(active substance)**

Test and Study Reports

Document K (formulation)

Individual test and study reports in accordance with the legislative requirements of the country to which application is made (Figure 1) - for the convenience of evaluators, separate dossiers should be provided for the active substance (Technical Grade Active Ingredient, which may contain more than one Active Ingredient Component) and formulated products. Where the registration of more than one formulation is requested, a separate dossier on each plant protection product for which a registration is requested should be provided;

**Documents
L – N**

Dossier Summaries

A summary, evaluation and assessment of the dossier of data and information submitted by the applicant, prepared in accordance with the tiered structure described here under, and presented graphically in Figure 1, to include:

**Document L
(active substance)
(Tier I)**

For the individual tests and studies submitted, reports as to their quality, prepared by or on behalf of the applicant, together with a list of the test, study reports and documents submitted - see also paragraphs 3.1.1 and 3.2.1,

Document L (formulation)

**Document L
(reference lists)**

**Document M
(active substance)
(Tier II)**

A comprehensive summary and assessment of the individual tests and studies and groups of tests and studies, as appropriate, in the light of relevant evaluative and decision making criteria - see also paragraphs 3.1.2 and 3.2.2;

Document M (formulation)

where relevant, to include an evaluation, cross referenced to the supporting documentary evidence, of the relevance of particular studies conducted regionally to the agricultural, plant health and environmental (including climatic) conditions of other regions, together with the rationale for extrapolations proposed,

Document N

(Tier III)

An overall summary and assessment of the application in the light of relevant evaluative and decision making criteria, the conclusions reached by the applicant on the basis of the data and information submitted, together with a statement of the proposed conditions and restrictions to be associated with any approval or registration granted, supported with the rationale for the proposals made - see also paragraphs 3.3.1 to 3.3.5, and


Document O

Completeness Check Forms

A completed set of the forms for the checking of dossiers for completeness (evaluation forms 1, 2, 3, and 4 - see paragraphs 4.1 to 4.2.4).

Figure 1

DOSSIER STRUCTURE AND CONTENT



2 Documentation Required

2.3 Samples and Analytical Standards

Where requested, a sample of each active substance as manufactured and which complies with the specification(s) submitted, together with analytical standards and of analytical standards for inactive isomers and impurities of toxicological or environmental concern present in significant quantities in the active substance as manufactured, should be provided.

3.1 Dossier on the active substance

3 DOSSIER SUMMARIES AND OVERALL ASSESSMENTS: DETAILED REQUIREMENTS

3.1 Dossier on the active substance

3.1.1 *Tier I* - Document L (active substance) - Checks as to the acceptability of the quality of individual test and study reports relating to the active substance

- (i) The dossier summary should, in principle, include a report as to the acceptability of the quality of each individual test and study submitted to address each relevant data requirement. Those reports should be assembled in sections as specified in subparagraph (xvi). To facilitate completeness checks, data requirements for pheromones and other semiochemicals should be addressed at least by a justification for waiving, which should occur in lieu of a specific report. (See Appendix 5, Part 4 and Appendix 10)
- (ii) The *Tier I* checks as to the acceptability of the quality of individual test and study reports to be submitted are intended to facilitate efficiency in the use of the resources available to the regulatory authorities for the evaluation of dossiers (scientific secretariats and specialist evaluators). In particular they are intended to facilitate the checking of dossiers as to completeness and format, checks to ensure compliance with the principles of GLP or GEP², as appropriate and, checks relating to the suitability of test methods used.
- (iii) In the case of testing as to the physical and chemical properties of active substances and by way of exception, it is not necessary that reports as to the quality of individual tests be provided. Details of the methodologies used should be provided in the *Tier II* summary (see paragraph 3.1.2) and instances of non compliance with or, of divergence or omissions from the requirements relating to the principles of GLP or GEP, as appropriate, should be indicated and be justified for each individual test or study.
- (iv) Where the test methods used were those currently specified, and where the tests or studies concerned were conducted in accordance with the principles of GLP/GEP, as appropriate, *Tier I* checks as to the acceptability of the quality of individual test and study reports should take the form (examples are provided in Part 1 of Appendix 4):
 - 1.1 the data point addressed (*cf* subparagraph xvi),
 - 1.2 a description of the type of test or study;
 - 2 reference point (location) of the report in the dossier (*e.g.* section 3, point 5.2.1/01);
 - 3.1 the names of the authors,
 - 3.2 the title of the test or study report,
 - 3.3 the owner of the report,
 - 3.4 an indication as to whether it is a published or unpublished report,
 - 3.5 the report number,
 - 3.6 the date of the report;
 - 4.1 the name and address of the testing facility,
 - 4.2 the laboratory report/project number;
 - 5 the dates of commencement and completion of experimental work;
 - 6.1 the identity of the test substance or material (ISO common name, batch number and degree of purity),
 - 6.2 an explicit reference to the relevant specification of composition of the test

- substance or material;
- 7.1 the identity of the test guideline used,
- 7.2 where test guidelines provide choice as to the method to be used, a reasoned justification for the method used,
- 7.3 where deviations from the test guidelines specified are employed, a description of and reasoned justification for the deviations;
- 8 confirmation that the principles of GLP or GEP, as appropriate, were complied with - in the event of non-compliance a description of the degree of non-compliance and a justification for non-compliance.
- (v) For tests and studies for which the test methods used were not those currently specified (*i.e.* studies conducted in accordance with test guidelines which have been replaced or were never accepted), a more detailed approach is necessary in which each of the following points should be addressed in the *Tier I* checks as to the acceptability of the quality of individual test and study reports - where a particular heading is not relevant, the reason that it is not relevant should be stated. (See Appendix 10, Part 5)
- (vi) A number of specimens of *Tier I* checks as to the acceptability of the quality of individual test and study reports for studies conducted in accordance with test guidelines other than those specified, are contained in Part 2 of Appendix 3.
- (vii) It is not necessary that *Tier I* checks as to acceptability of the quality of reports be provided for reports relating to analytical methods, regardless of whether the methods concerned relate to residues analysis, analysis of active substance as manufactured or analysis of formulations. Details of the methods of analysis concerned should be provided in the *Tier II* summary and evaluation (see paragraph 3.1.2 viii and Appendix 5, Part 2).
- (viii) The final part of *Tier I* of the summary dossier should comprise a listing of all test and study reports, test guidelines, and published papers, submitted as part of the dossier and a separate listing of all test and study reports, test guidelines, and published papers, not submitted as part of the dossier, of which the applicant is aware and which are relevant to the regulatory decision proposed (*i.e.* those that address relevant end-points). It is to be noted that applicants are obliged to submit all relevant information of which they are aware concerning potentially dangerous effects, not just a reference to such reports and papers.
- (ix) In preparing the listing, applicants should conduct a detailed literature search - expert judgement is required to determine the nature and extent of the search to be conducted. The date on which the reference list was compiled, the identity of the data bases searched, the date range established for the purposes of the search (*e.g.* abstracts dated earlier than 1980 not requested), the language constraints, if any, imposed and the key words used for the purposes of the literature search, should be indicated.
- (x) The listing of test and study reports, test guidelines, and published papers submitted as part of the complete dossier, should cover each section of the dossier separately. References which relate to more than one section should be listed in each relevant section. Within sections, for each point, and where appropriate, sub-point, the list should be arranged alphabetically by author. Where for a particular author there is more than one report or paper, they should be listed in chronological order, with the most recent report or paper listed last. In cases where for a particular author, more than one reference is listed for any one year, the references should be distinguished by inserting letters after the year *i.e.* a, b, c, *etc.*,

as appropriate. For each test and study report, an indication should be provided as to whether or not it is published and as to whether or not it was conducted in compliance with the principles of GLP or the principles of GEP, as appropriate. The listing of individual test and study reports should be annotated to indicate their owner and to indicate whether or not data protection is claimed in accordance with the relevant rules in place in the country to which the dossier is submitted. Before regulatory decisions are made, applicants will be required, where appropriate, to certify that the studies for which they have claimed data protection, have or have not been submitted in support of other applications. A suggested format for the presentation of the listings of test and study reports, test guidelines, and published papers submitted is contained in Part 1 of Appendix 5. In order to facilitate the subsequent manipulation of the reference list by the regulatory authority, the listing should be compiled using a word processing table function, using a separate row for each reference.

- (xi) A second version of the listing of test and study reports, test guidelines, and published papers, submitted as part of the complete dossier, which should again cover each section of the dossier separately, but in which the tests and studies are listed alphabetically by author and for individual authors, in chronological order, should be provided. A suggested format for the presentation of the second listing of test and study reports, test guidelines, and published papers submitted is contained in Part 2 of Appendix 5. In order to facilitate the subsequent manipulation of the reference list by the regulatory authority to which it is submitted, the listing should be compiled using a word processing table function, using a separate row for each reference.
- (xii) In the case of test and study reports and published papers not submitted, a separate listing of such documents, arranged alphabetically by author, should be provided at the end of each section. A suggested format for the presentation of the listings of test and study reports and published papers not submitted is contained in Part 3 of Appendix 5. In order to facilitate the subsequent manipulation of the reference list by the regulatory authority to which it is submitted, the listing should be compiled using a word processing table function, using a separate row for each reference.
- (xiii) The separate sections for which a listing of test and study reports, test guidelines, and published papers is required are as follows:

- | | |
|-----------|---|
| Section 1 | <ul style="list-style-type: none">• Identity of the active substance,• Physical and chemical properties of the active substance,• Further information on the active substance (function; effects on harmful organisms; field of use; harmful organisms controlled and crops or products protected or treated; mode of action; information with respect to resistance and resistance management strategies; recommended methods and precautions concerning handling, storage, transport or fire; procedures for destruction or decontamination),• Proposals including justification for the proposals for the classification and labelling of the active substance; |
|-----------|---|

Section 2 Analytical methods;

Section 3	Toxicological and metabolism studies on the active substance;
Section 4	Residues (generally not required)
Section 5	Fate and behaviour in the environment; and
Section 6	Ecotoxicological studies on the active substance.

- (xiv) For the purposes of avoiding confusion and facilitating the examination of dossiers submitted, a compilation of all chemical names, common names, synonyms and code names, used for the active substance and its metabolites should be appended to *Tier I* of the summary dossier. For each compound, its chemical name followed by all other names used, should be listed. The approach suggested for the preparation of compilations of chemical names, common names, synonyms and code names for active substances and metabolites is illustrated in the listing comprising Part 4 of Appendix 1.
- (xv) The numbering systems used in many OECD countries for the data and information relating to active substances to be submitted, are different. Applicants should use the OECD numbering system, which may be found in Part 4 of Appendix 6, in submitting data and information appropriate to the country (or countries) to which application(s) is (are) being made. Alternatively, applicants can use the country-specific numbering system for the country to which application is being made. A compilation of the numbering systems used in some OECD countries is included in Part 4 of Appendix 6.

3.1 Dossier on the active substance

3.1.2 *Tier II* - Document M (active substance) - Summary and assessment of the dossier relating to the active substance

- (i) The *Tier II* summary for an active substance should contain six sections such that it contains a discussion and interpretation of the results of all the tests and studies which relate to the active substance and within each section, the conclusions reached. The five sections are those specified in paragraph 3.1.1 (xvi).
- (ii) Where relevant and necessary (e.g. registration of a plant protection product) efficacy data and information is required in some countries. However, such information is relevant to the formulation rather than to the active substance. It therefore is neither necessary nor appropriate that the *Tier II* summary for the active substance include such information.
- (iii) The *Tier II* summary should be confined to and rely only on that data and information contained in the active substance dossier provided. If desired, a reference to the corresponding formulation summary or summaries can be included.
- (iv) In the case of non submission of particular studies, (as shown in Appendix 7, Part 3), full justifications should be provided.
- (v) Where the principles of GLP or of GEP have not been followed, or where the methodologies used were not those currently prescribed in the country to which application is being made or, where there were deviations from the methods prescribed or other methods used, a justification of the overall quality and scientific validity of the test or study reported should be provided.
- (vi) As a general rule, a concise but comprehensive summary of each individual test and study should be included. Each summary should include the following elements, as appropriate:
 - the reference number of the test or study;
 - the appropriate test or study reference (e.g. Casida *et al* 1979);
 - the test guideline and method used;
 - relevant GLP/GEP information;
 - a brief description of the methodology used;
 - a concise tabular presentation of the findings with supporting text, in which the significance of results obtained, effects and observations reported, are highlighted; and
 - conclusions reached (to be highlighted);
- (vii) By way of exception to the general rule, in the case of certain parts of the dossier such as that relating to the *physical and chemical properties of the active substance*, a tabular approach to the presentation of the data may be appropriate.
- (viii) Examples of parts of a *Tier II* summary for an active substance are provided in Appendix 7 - Part 1 contains the suggested format for that part of a *Tier II* summary which relates to the *physical and chemical properties of the active substance*, Part 2 contains the suggested format for part of a *Tier II* summary relating to *analytical methods*, while Part 3 contains an example of part of a *Tier II* summary relating to *toxicological and metabolism studies*. An example of part of a *Tier II* summary relating to fate and behaviour in the environment is provided in Part 5 of Appendix 7.

- (ix) For each of the five sections of the *Tier II* summary, it is particularly important that the concluding element for each point and the concluding element of sub-sections and sections, highlight the parameters of relevance to decision making, and include the rationale relied on for the conclusions reached in the light of the weight of evidence provided by the data reported. In this context it may be of particular relevance for pheromones and other semiochemicals to discuss the justification for waiving certain data requirements in full detail. The aim must be to fully justify that the substance poses no unacceptable risk although not all endpoints have been addressed by experimental studies. An example is given in Appendix 7, Section 3).
- (x) Where relevant, an evaluation, cross referenced to the supporting documentary evidence, of the relevance of particular studies conducted regionally to the agricultural, plant health and environmental (including climatic) conditions of other regions, together with the rationale for extrapolations proposed, should be included.
- (xi) Within each section and sub-section, having regard to the data provided, it is necessary that each decision making point be highlighted, having regard to:
- the weight of the evidence available - extent, quality and consistency of the data; and
 - the criteria and guidelines for evaluation and decision making currently used in the country to which application is made.

3.2 Dossier on the formulated product

3.2 Dossier on the formulated product

3.2.1 *Tier I* - Document L (formulation) - Checks as to the acceptability of the quality of individual test and study reports relating to the formulated product

- (i) The dossier summary should, in principle, include a report as to the acceptability of the quality of each individual test and study submitted to address each point of the data requirements. Those reports should be compiled in seven Sections as specified in subparagraph (xviii). To facilitate completeness checks, data requirements for pheromones and other semiochemicals should be addressed at least by a justification for waiving, which should occur in lieu of a specific report. (See Appendix 4)
- (ii) Where application is made for the approval or continued approval of an active substance, in order to ensure that any approval granted embraces all uses that are being supported, without unnecessary conditions and restrictions, thereby facilitating registration of formulations containing the active substance for all such uses, the number of formulations for which a dossier is submitted should be sufficient to reflect the types of formulations and applications envisaged, as well as worst case scenarios for operator, worker and environmental exposure.
- (iii) The *Tier I* checks as to the acceptability of the quality of individual test and study reports to be submitted are intended to facilitate efficiency in the use of the resources available to the regulatory authorities for the evaluation of dossiers (scientific secretariats and specialist evaluators). In particular they are intended to facilitate the checking of dossiers as to completeness and format, checks to ensure compliance with the principles of GLP or GEP, as appropriate and, checks relating to the suitability of test methods used.
- (iv) In the case of testing as to the physical, chemical and technical properties of formulated products and by way of exception, it is not necessary that reports as to the quality of individual tests be provided. Details of the methodologies used should be provided in the *Tier II* summary (see paragraph 3.2.2) and instances of non compliance with or, of divergence or omissions from the requirements relating to the principles of GLP or GEP, as appropriate, should be indicated and be justified for each individual test or study.
- (v) Efficacy data and information must be submitted in support of applications for the registration of individual plant protection products in many but not all countries. It is not necessary, that reports as to the quality of individual tests and trials be provided. Details of the methodologies used should be provided in the *Tier II* summary (see paragraph 3.2.2) and instances of non compliance with or, of divergence or omissions from the requirements relating to the principles of GEP should be indicated and be justified for each individual test or trial.
- (vi) Where the test methods used were those currently specified, and where the tests or studies concerned were conducted in accordance with the principles of GLP/GEP, as appropriate, *Tier I* checks as to the acceptability of the quality of individual test and study reports should take the following form (examples are provided in Part 1 of Appendix 4):
 - 1.1 the data point addressed (*cf* subparagraph xviii),
 - 1.2 a description of the type of test or study;

- 2 reference point (location) of the report in the dossier (e.g. section 3, point 7.1.4 /01);
 - 3.1 the names of the authors,
 - 3.2 the title of the test or study report,
 - 3.3 the owner of the report,
 - 3.4 an indication as to whether it is a published or unpublished report,
 - 3.5 the report number,
 - 3.6 the date of the report;
 - 4.1 the name and address of the testing facility,
 - 4.2 the laboratory report/project number;
 - 5 the dates of commencement and completion of experimental work;
 - 6.1 the identity of the test substance or material (brand name, batch number and degree of purity),
 - 6.2 an explicit reference to the relevant specification of composition of the test substance or material;
 - 7.1 the identity of the test guideline used,
 - 7.2 where test guidelines provide choice as to the method to be used, a reasoned justification for the method used;
 - 7.3 where deviations from the test guidelines specified are employed, a description of and reasoned justification for the deviations;
 - 8 confirmation that the principles of GLP or GEP, as appropriate, were complied with - in the event of non-compliance a description of the degree of non-compliance and a justification for non-compliance.
- (vii) For tests and studies for which the test methods used were not those currently specified (*i.e.* studies conducted in accordance with test guidelines which have been replaced or were never accepted), a more detailed approach is necessary in which each of the following points should be addressed in the *Tier I* checks as to the acceptability of the quality of individual test and study reports - where a particular heading is not relevant, the reason that it is not relevant should be stated (See Appendix 4):
- (viii) The suggested format for the presentation of *Tier I* checks as to the acceptability of the quality of individual test and study reports for tests and studies on formulated products is the same as that for tests and studies relating to active substances, as presented Appendix 4.
- (ix) It is not necessary that *Tier I* checks as to acceptability of the quality of reports be provided for reports relating to analytical methods.
- (x) The final part of *Tier I* of the summary dossier should comprise a listing of all test and study reports, test guidelines, and published papers, submitted as part of the dossier and a separate listing of all test and study reports, test guidelines, and published papers, not submitted as part of the dossier, of which the applicant is aware and which are relevant to the regulatory decision proposed (*i.e.* those that address relevant end-points). It is to be noted that applicants are obliged to submit all relevant information of which they are aware concerning potentially dangerous effects, not just a reference to such reports and papers.
- (xi) In preparing the listing, applicants should conduct a detailed literature search - expert judgement is required to determine the nature and extent of the search to be conducted. The date on which the reference list was compiled, the identity of the data bases searched, the

date range established for the purposes of the search (*e.g.* abstracts dated earlier than 1980 not requested), the language constraints, if any, imposed and the key words used for the purposes of the literature search, should be indicated.

- (xii) The listing of test and study reports, test guidelines, and published papers submitted as part of the complete dossier, should cover each section of the dossier separately. References which relate to more than one section should be listed in each relevant section. Within sections, for each point, and where appropriate, sub-point, the list should be arranged alphabetically by author. Where for a particular author there is more than one report or paper, they should be listed in chronological order, with the most recent report or paper listed last. In cases where for a particular author, more than one reference is listed for any one year, the references should be distinguished by inserting letters after the year *i.e.* a, b, c, *etc.*, as appropriate. For each test and study report, an indication should be provided as to whether or not it is published and as to whether or not it was conducted in compliance with the principles of GLP or the principles of GEP, as appropriate. The listing of individual test and study reports should be annotated to indicate their owner and to indicate whether or not data protection is claimed in accordance with the relevant rules or provisions in place in the country to which the dossier is submitted. Before regulatory decisions are made, applicants will be required, where appropriate, to certify that the studies for which they have claimed data protection, have or have not been submitted in support of other applications. A suggested format for the presentation of the listings of test and study reports, test guidelines, and published papers submitted is contained in Part 1 of Appendix 6. In order to facilitate the subsequent manipulation of the reference list by the regulatory authority to which it is submitted, the listing should be compiled using a word processing table function, using a separate row for each reference.
- (xiii) A second version of the listing of test and study reports, test guidelines, and published papers, submitted as part of the complete dossier, which should again cover each section of the dossier separately, but in which the tests and studies are listed alphabetically by author and for individual authors, in chronological order, should be provided. A suggested format for the presentation of the second listing of test and study reports, test guidelines, and published papers submitted is contained in Part 2 of Appendix 6. In order to facilitate the subsequent manipulation of the reference list by the regulatory authority to which it is submitted, the listing should be compiled using a word processing table function, using a separate row for each reference.
- (xiv) In the case of test and study reports and published papers not submitted, a separate listing of such documents, arranged alphabetically by author, should be provided at the end of each section. A suggested format for the presentation of the listings of test and study reports and published papers not submitted is contained in Part 3 of Appendix 6. In order to facilitate the subsequent manipulation of the reference list by the regulatory authority to which it is submitted, the listing should be compiled using a word processing table function, using a separate row for each reference.
- (xv) The separate sections for which a listing of test and study reports, test guidelines, and published papers is required are as follows:

- Section 1
- Identity of the plant protection product,
 - Physical, chemical and technical properties of the plant protection product,
 - Data on application (field of use; effects on harmful organisms; details of intended use - harmful organisms controlled and/or plants or plant products to be protected; application rate; concentration of active substance in material used; method of application; number and timing of applications and duration of protection; necessary waiting periods or other precautions to avoid phytotoxic effects on succeeding crops; proposed instructions for use),
 - Further information on the plant protection product (packaging details and compatibility of the preparation with proposed packaging materials; procedures for cleaning application equipment; re-entry periods, necessary waiting periods or other precautions to protect man, livestock and the environment; recommended methods and precautions concerning handling, storage, transport or fire; emergency measures in the case of an accident; procedures for destruction or decontamination of the plant protection product and its packaging), and
 - Proposals including justification for the classification and labelling (risk and safety phrases) of the plant protection product, and
 - Proposed label for the plant protection product;
- Section 2 Analytical methods;
- Section 3 Toxicological studies and exposure information and data (operators - mixers, loaders and applicators; workers; bystanders);
- Section 4 Residues (generally not required)
- Section 5 Fate and behaviour in the environment;
- Section 6 Ecotoxicological studies and risk assessment; and
- Section 7 Efficacy data and information (effectiveness; resistance; effects on the quality of plants and plant products; effects on yield of treated plants or plant products; phytotoxicity to target plants or plant products; economics; benefits).

- (xvi) For the purposes of avoiding confusion and facilitating the examination of dossiers submitted, a compilation of all chemical names, common names, synonyms, trade names and code names, used for the active substance, preparations containing it and metabolites of the active substance should be appended to Tier I of the summary dossier. For each compound, its chemical name followed by all other names used, should be listed, while for each preparation its current name followed by all other names used should be listed. The approach suggested for the preparation of compilations of chemical names, common names, synonyms and code names for active substances, metabolites and formulation is illustrated in the listing comprising Part 3 of Appendix 1.

- (xvii) The numbering systems used in many OECD countries for the data and information relating to formulated products to be submitted, are different. Applicants should use the OECD numbering system which may be found in Part 5 of Appendix 6 for submitting data and information appropriate to the country (or countries) to which application(s) is (are) being made. Alternatively, applicants can use the country-specific numbering system for the country to which application is being made. A compilation of the numbering systems used in some OECD countries is included in Part 5 of Appendix 6.

3.2.2 *Tier II* - Document M (formulation) - Summary and assessment of the dossier relating to the formulated product

- (i) The *Tier II* summary for a plant protection product should contain seven sections such that it contains a discussion and interpretation of the results of all tests and studies relating to the formulation and within each section, the conclusions reached. The seven sections are those listed in paragraph 3.2.1 (xviii).
- (ii) Where relevant and necessary (*e.g.* registration of a plant protection product), the final section (Section 7 - Efficacy) should be included. The separate elements to be addressed in the section on efficacy include effectiveness, potential for the development of resistance, effects on the quality of plants and plant products, effects on yield of treated plants or plant products and phytotoxicity to target plants or plant products). Guidelines for the preparation and presentation of efficacy data have been issued by some countries *e.g.* European Union³.
- (iii) *Tier II* summaries, which should consist of a discussion and interpretation of the results of the tests and studies contained in the dossier for the formulated product provided, for the purposes of that discussion and interpretation, should draw on data and information contained in the relevant active substance dossier(s).
- (iv) In the case of non submission of particular studies, (as shown in Appendix 8), full justifications should be provided.
- (v) Where the principles of GLP or GEP have not been followed, or where the methodologies used were not those currently prescribed in the country to which application is being made or, where there were deviations from the methods prescribed or other methods used, a justification of the overall quality and scientific validity of the test or study reported should be provided.
- (vi) As a general rule, a concise but comprehensive summary of each individual test and study should be included. Each summary should include the following elements, as appropriate:
 - the reference number of the test or study;
 - the appropriate test or study reference (*e.g.* Casida *et al* 1979);
 - the test guideline and method used;
 - relevant GLP/GEP information;
 - a brief description of the methodology used;
 - a concise tabular presentation of the findings with supporting text in which the significance of results obtained, effects and observations reported, are highlighted; and
 - conclusions reached (to be highlighted);
- (vii) By way of exception to the general rule, in the case of certain parts of the dossier such as Section 1 a tabular approach to the presentation of the data may be appropriate.
- (viii) Examples of parts of an Annex III *Tier II* summary are provided in Appendix 8:
 - Part 1 contains an example of that part of a *Tier II* summary which relates to the

- identity of the plant protection product; physical, chemical and technical properties of the plant protection product; data on application; and further information on the plant protection product;*
- Part 2 contains an example of a *Tier II* summary relating to *toxicological studies and exposure information and data;*
 - Part 3 contains an example of a *Tier II* summary relating to *ecotoxicological studies and risk assessment;* and
 - Part 4 contains an example of a *Tier II* summary relating to *efficacy testing.*
- (ix) For each of the seven Sections of the *Tier II* summary, it is particularly important that the concluding element for each point and the concluding element of sub-sections and sections, highlight the parameters of relevance to decision making, and include the rationale relied on for the conclusions reached in the light of the weight of evidence provided by the data reported. In this context it may be of particular relevance for plant protection products containing exclusively pheromones and semiochemicals as active substances to discuss the justification for waiving certain data requirements in full detail. The aim must be to fully justify that the product poses no unacceptable risk although not all endpoints have been addressed by experimental studies. An example is given in Appendix 8, Parts 2 and 3).
- (x) Where relevant, an evaluation, cross referenced to the supporting documentary evidence, of the relevance of particular studies conducted regionally to the agricultural, plant health and environmental (including climatic) conditions of other regions, together with the rationale for extrapolations proposed, should be included.
- (xi) Within each section and sub-section, having regard to the data provided, it is necessary that each decision making point be highlighted, having regard to:
- the weight of the evidence available - extent, quality and consistency of the data; and
 - the criteria and guidelines for evaluation and decision making currently used in the country to which application is made.

3.3 Overall Summary and Assessment (active substance and formulated product dossiers) -
Tier III - Document N

3.3 Overall Summary and Assessment (active substance and formulated product dossiers) - *Tier III* -
Document N

3.3.1 This, the final evaluation level, should involve an integration of the results obtained and conclusions drawn on the basis of the tests, studies and information provided relating to both the active substance(s) and the formulated product(s). The order in which the various elements should be presented is indicated in Table 1.

3.3.2 The *Tier III* overall summary and assessment should contain a concise summary of the data base presented in the active substance and formulated product dossiers. That summary should be supported with a detailed statement of the applicant's overall assessment of the dossier, and should contain a reasoned statement of the conclusions which the applicant believes should be reached on the basis of the data and information provided, having regard to:

- the weight of the evidence available - the extent, quality and consistency of the data;
- the criteria and guidelines for evaluation and decision making currently used in the country to which application is made.

3.3.3 The assessment of the data base provided, should establish the rationale for the decision to be taken. It is especially important that the overall assessment of the data base prepared include details of the conditions and restrictions to be associated with any approval or registration to be granted, together with a detailed justification for the proposals made. A listing of all end points which are used in or are relevant to the proposed decision should be appended to the *Tier III* overall summary and assessment. In order to ensure a consistent approach in preparing the listing of end points, the format illustrated in Appendix 9 should be used.

3.3.5 An example of a *Tier III* summary and overall assessment is provided in Appendix 10.

3.3 Overall Summary and Assessment (active substance and formulated product dossiers) -
Tier III - Document N

Table 1 **Order in which the reasoned statement of the conclusions reached by the applicant are to be presented**

Chapter 1	The active substance, its properties, uses, proposed classification and labelling
1.1	Identity
1.2	Physical and chemical properties
1.3	Details of uses and further information
1.4	Classification and labelling
Chapter 2	Methods of analysis
2.1	for analysis of the active substance as manufactured
2.2	for formulation analysis
Chapter 3	Impact on human and animal health
3.1	Effects having relevance to human and animal health arising from exposure to the active substance or to impurities contained in the active substance or to their transformation products
Chapter 5	Fate and behaviour in the environment
Chapter 6	Effects on non-target species
Chapter 7	Efficacy data and information
7.1	Effectiveness
7.5	Observations on undesirable or unintended side effects <i>e.g.</i> on beneficial and other non-target organisms, on succeeding crops, other plants or parts of treated plants used for propagating purposes (<i>e.g.</i> seeds, cuttings, runners)
Final Chapter	Overall conclusions Proposed decision Further information to be submitted

Chapter 4 Residues (not normally required)

4 CHECKING OF DOSSIERS FOR COMPLETENESS

4.1 Introduction

The guidance and forms provided herewith, are for use in checking dossiers for completeness, whether such dossiers are to be submitted in support of an application for approval of an active substances for the registration of a plant protection product, or in the context of the review or renewal of any such approval, or registration. It is intended that the forms be completed by applicants and be submitted as part of the application submitted (Document O).

4.2 Suggested Approach

4.2.1 The nature and extent of the check for completeness should be such that it is confirmed that:

- (i) all the required supporting documentation has been included (Documents A to J);
- (ii) the *Tier I* checks as to the acceptability of individual test and study reports, the *Tier II* dossier summaries and assessments and the *Tier III* overall summary and assessment, have been included;
- (iii) all test and study reports relating to the active substance required in accordance with the requirements specified for the country to which application is made (Document K active substance) or, in the case of particular test and study reports, either a justification for non provision, or an undertaking to provide them at a future specified date, have been provided; and
- (iv) all test and study reports relating to the formulated product required in accordance with the requirements specified for the country to which application is made (Documents K formulation) or, in the case of particular test and study reports, either a justification for non provision, or an undertaking to provide them at a future specified date, have been provided.

4.2.2 Some of the forms necessary for checking dossiers for completeness are provided in Appendix 11. Other forms necessary for that purpose, as indicated here under, have been developed, or are to be developed by the regulatory authorities of individual countries, or groups of countries (*e.g.* EU), as appropriate:

	Evaluation Form 1	for use in checking that the required supporting documentation has been provided	Appendix 11, Part 1
	Evaluation Form 2	for use in checking that the required active substance and formulated product dossier summaries and an overall assessment, have been provided	Appendix 11, Part 2
	Evaluation Form 3	for use in checking that all test and study reports relating to the active substance which are required, have been provided	Appendix 11, Part 3
	Evaluation Form 4	for use in checking that all test and study reports relating to the formulated product which are required, have been provided	Appendix 11, Part 4
4.2.3	A completed set of evaluation forms 1, 2, 3 and 4 (Document O - hard copy and/or diskette) must accompany each dossier submitted. The completed forms will be used, by the regulatory authority of the country to which application is made, in conducting its initial evaluation of the dossier to check it for completeness.		
4.2.4	Although it is not necessary that completed forms be submitted, forms and supporting documentation for use in checking the acceptability of the quality of individual test and study reports, are also provided in Appendix 11 -		
	Evaluation Form 5	for use in checking that the <i>Tier I</i> quality checks for individual test and study reports, conducted in accordance with test methods other than those currently specified, are themselves of acceptable quality.	Appendix 11, Part 5
	S u p p o r t i n g document	Listing of the test guidelines specified and the requirements relating to compliance with GLP and GEP for individual tests and studies relating to the active substance	regulatory authorities of individual countries
	S u p p o r t i n g document	Listing of the test guidelines specified and the requirements relating to compliance with GLP and GEP for individual tests and studies relating to the formulated product	regulatory authorities of individual countries

Endnotes:

1. Particular attention is drawn to the requirement to use metric units - *e.g.* in the case of application rates, kg active substance/ha; content of active substance in formulations, g/kg or g/l; content of residues, mg/kg; doses in feeding studies, mg/kg body weight. Where it is necessary that other units be used, conversion factors should be provided.
2. The principles of GEP (*Good Experimental Practice*) are analogous to the principles of GLP, but are less onerous in terms of the requirements and procedures relating to quality assurance, inspection and auditing. In the European Union, GEP is obligatory for those tests and studies to which GLP does not apply (*e.g.* technical properties of formulations, efficacy and phytotoxicity tests)
3. Commission Document 7600/VI/95, rev 6 of 14 July 1997, Guidelines and criteria for the preparation and presentation of data concerning efficacy as provided in Annex III, parts A and B, section 6 of Directive 91/414/EEC concerning the placing of plant protection products on the market (biological assessment dossier)